Skip to main content

LCD L40179: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)

LCD L40179, Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC), is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2026-03-01. The policy text runs 1,700 words, and its billing and coding article A60185 lists 51 ICD-10-CM codes that support medical necessity for 5 procedure codes. 4 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 51 covered ICD-10-CM codes: the same total as L40168 (Wellpoint Federal, 51 codes, revised 2026-04-01) and the same total as L40176 (Noridian Healthcare Solutions, LLC, 51 codes, revised 2026-03-01).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2026-03-01
Original effective
2026-03-01
Policy text
1,700 words
Covered ICD-10 codes (articles)
51

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L40179
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Billing and coding article A60185: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A60185 (Billing and Coding: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A60185: Billing and Coding: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC) (Billing and Coding, effective 2026-03-01)

Covered ICD-10-CM codes
51
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
5
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A60185
ICD-10-CMDescription (FY2027)
C44.01Basal cell carcinoma of skin of lip
C44.02Squamous cell carcinoma of skin of lip
C44.1121Basal cell carcinoma of skin of right upper eyelid, including canthus
C44.1122Basal cell carcinoma of skin of right lower eyelid, including canthus
C44.1191Basal cell carcinoma of skin of left upper eyelid, including canthus
C44.1192Basal cell carcinoma of skin of left lower eyelid, including canthus
C44.1221Squamous cell carcinoma of skin of right upper eyelid, including canthus
C44.1222Squamous cell carcinoma of skin of right lower eyelid, including canthus
C44.1291Squamous cell carcinoma of skin of left upper eyelid, including canthus
C44.1292Squamous cell carcinoma of skin of left lower eyelid, including canthus
C44.212Basal cell carcinoma of skin of right ear and external auricular canal
C44.219Basal cell carcinoma of skin of left ear and external auricular canal
C44.222Squamous cell carcinoma of skin of right ear and external auricular canal
C44.229Squamous cell carcinoma of skin of left ear and external auricular canal
C44.311Basal cell carcinoma of skin of nose
C44.319Basal cell carcinoma of skin of other parts of face
C44.321Squamous cell carcinoma of skin of nose
C44.329Squamous cell carcinoma of skin of other parts of face
C44.41Basal cell carcinoma of skin of scalp and neck
C44.42Squamous cell carcinoma of skin of scalp and neck
C44.510Basal cell carcinoma of anal skin
C44.511Basal cell carcinoma of skin of breast
C44.519Basal cell carcinoma of skin of other part of trunk
C44.520Squamous cell carcinoma of anal skin

Procedure codes: 77336, 77370, 77436, 77437, 77439.

Coverage indications, limitations and medical necessity

Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and General Information

Nonmelanoma skin cancers (NMSC) such as squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) are a type of keratinocyte carcinoma and are the most common malignancies reported in the United States of America(U.S.). 1-3 In 2015, Rogers et al. analyzed claims data from 2006 through 2012 for total claims filed in both the Total Claims Data Set and the Medicare Limited Data Set and found that NMSC was the most common malignancy treated based upon CPT codes. In addition, they noted that the incidence of diagnosed NMSC increased 35% from 2006 through 2012. 2 Unfortunately, the prevalence of NMSC is generally not reported or tracked by national cancer registries. 3 However, the total number of procedures for skin cancer treatment in the Medicare population increased by 13% from 2,048,517 in 2006 to 2,321,058 in 2012. 2 Even though the exact prevalence of NMSC may be unknown, the American Cancer Society estimates that 5.4 million basal and squamous cell skin cancers are diagnosed each year in the U.S. occurring in approximately 3.3 million people. 3

There are multiple modalities available for the treatment of cutaneous NMSCs. Predication of treatment is often based upon the most reasonable alternative that will give the highest likelihood of cure with the least associated morbidity. Such treatment options include electrodessication and curettage, topical chemotherapeutic agents, simple surgical excision, complex surgical excision with or without frozen section, micrographically oriented histographic surgery (Mohs), external beam radiation therapy (EBRT), and SRT including electronic brachytherapy (EBT). 4,5,7-13 More recently, there have been some reports of combining the use of high-resolution ultrasound (HRUS) imaging with SRT or EBT in order to guide delivery and assess lesion reduction; the effectiveness of this additional modality is currently under active investigation. 14-19

According to the National Comprehensive Cancer Network ® (NCCN ® ) and the American Academy of Dermatology Association (AAD) guidelines, treatment is based upon the stratification of SCC and BCC into risk factors based upon the likelihood of recurrence. 4,5,8,9 Per NCCN ® guidelines for BCC, 4 the stratification elucidated below should be used to determine the treatment for local BCC based on the following risk factors for recurrence (any high-risk factor places the patient into the high-risk stratification group): low-risk BCC and high-risk BCC.

Similarly, NCCN ® stratification guidelines for local SCC or SCC in situ are based on risk factors for recurrence and are stratified into low-risk, high-risk and very high-risk. 5 Risk category assignment should be based on the highest risk factor present. The high-risk group has elevated risk of local recurrence; the very-high-risk group has elevated risk of local recurrence and elevated risk of metastasis. Deep invasion for SCC is defined as invasion beyond the subcutaneous fat OR >6 mm (as measured from the granular layer of adjacent normal epidermis to the base of the tumor, consistent with the American Joint Committee on Cancer (AJCC) Staging Manual, 8th Edition). 20 The very high-risk SCC is not amenable to SRT, and the depth is measured before any preoperative curettage or other treatment to the lesion.

Narrow excision margins, due to anatomic and functional constraints, are associated with increased recurrence rates with standard histological processing. Complete margin assessment such as with Mohs or peripheral and deep en face margin assessment (PDEMA) is recommended for optimal tumor clearance and maximal tissue conservation per NCCN ® guidelines for both SCC and BCC. 4,5 Very high-risk SCC should be treated with surgical excision with PDEMA or Mohs micrographic surgery (MMS) with/without adjuvant RT based upon consultation with a radiation oncologist per NCCN ® guidelines OR EBRT. 5

Current published and recommended guidelines exist from NCCN ® , AAD, the American Society of Radiation Oncology (ASTRO), and the American Brachytherapy Society (ABS). Recommended treatment of cutaneous NMSC is based upon a consortium of experts and peer-reviewed literature. 4-11

The focus of this LCD will pull information from literature including published societal guidelines and published peer-reviewed articles. No changes are recommended for currently approved indications for EBRT and MMS for the treatment of NMSC. Peer-reviewed, published evidence on SRT and the subset on EBT will be utilized to help establish coverage limitations for these modalities in the Medicare population.

BCC is the most common form of human cancer with a continued increase in annual incidence and is closely followed by SCC in the U.S. 1-3,8,9 While several options for treatment exist, the majority of NMSCs are treated surgically, either with a traditional surgical excision or MMS.

SRT has also been a long-standing, optional treatment by dermatologists and radiation therapists but had been relegated to a second line treatment option for patients who were not surgical candidates or who refused surgical treatment. In addition, there are no prospective or randomized clinical trials (RCTs) in the peer-reviewed literature that compare the outcomes in recurrence rates (long-term 5 years or more, short-term less than 2 years) between MMS or surgical excisions and SRT. In addition, with the advent of newer SRT technology, the reported recurrence rates have improved and are near the MMS rates although there is no consistent reporting of the histology sub-types and comparison of sub-groups with the higher risk NMSCs that are typical of MMS procedures. 10-15,21-24 Furthermore, several authors have purported to using HRUS guided SRT and HRUS guided EBT as being more effective than SRT or EBT alone, although there are no randomized clinical studies or prospective studies to show that the additional use of high-resolution ultrasound guidance (HRUS) improves the short-term and long-term recurrence rates. 14-16

SRT utilizes x-rays or photons to deliver electromagnetic energy to cells that are rapidly dividing in order to stop mitosis. SRT machines deliver low energy Kilovoltage (kV) in the range of 50 to 150 kV per treatment. The machines used to deliver superficial treatment spare the deeper structures and are ideal for treating cutaneous malignancies. 13 EBT is a variation of SRT except that a high dose x-ray source is placed directly into a skin applicator close to the surface and provides a homogenous dose pattern in the treatment area to a specified depth. EBT also delivers low-energy radiation at a high dose rate through an application that is placed on the skin typically less than 120 kilovoltage photons (kVp) as compared to traditional brachytherapy. 13,25 Traditional isotope-based brachytherapy administers radiation therapy within or in contact with the body. Electronic brachytherapy does not require the application of a radioactive source. Both SRT and EBT can be produced by commercially available devices 10,13 and are being used in the outpatient dermatology office or radiation oncology setting.

Covered Indications

The medical record documentation must support the medical necessity for the use of SRT as the primary modality for treatment of the NMSC.

If the beneficiary meets all the criteria as outlined in the LCD, the use of SRT is considered reasonable and necessary for the following conditions:

• The presence of a low-risk cutaneous BCC or high-risk BCC as per NCCN ® , ASTRO, and AAD guidelines with documentation that the patient is a nonsurgical candidate, 4,8,10 OR

• The presence of a low-risk cutaneous SCC or high-risk SCC as per NCCN ® , ASTRO, and AAD guidelines with documentation that the patient is a nonsurgical candidate, 5,9,10 OR

• The presence of a cutaneous SCC in situ as per NCCN ® , ASTRO and AAD guidelines with documentation that the patient is a nonsurgical candidate. 5,9,10

Examples of nonsurgical candidates are patients where the surgery would cause loss of function, would result in significant morbidity, poor cosmesis in an anatomically sensitive area (e.g., ears, nose, lips, or eyelids), or when after documentation of shared decision making the patient refuses surgery as a treatment option.

Limitations

• Use of HRUS to guide SRT delivery and to assess lesion reduction during the superficial

radiation treatment protocol is not considered reasonable and necessary and is not supported by literature 10 .

• Based upon the consensus of the literature and the recommendations of the AAD, ASTRO and ABS, the use of EBT for the treatment of NMSCs is not considered reasonable and necessary at this time. There is insufficient long-term efficacy and safety data to support the use of electronic surface brachytherapy. 12,13,26 .

Limitations for SRT

The following are considered not reasonable and necessary:

• First line treatment option in surgical candidates.

• The use of SRT for the treatment of advanced BCC and SCC.

• The use of SRT for the treatment of patients with NMSCs who have contraindications to RT.

• Cutaneous tumors arising in previously irradiated fields or where overlapping fields would be expected.

• Cutaneous SCC with size greater than 4 cm 5 .

• Cutaneous BCC with size greater than 4 cm 14 .

• Cutaneous NMSCs with depth greater than 6 mm 5,14,19 .

• Cutaneous NMSCs with aggressive morphology 27,28 .

• Cutaneous tumors with perineural or perivascular invasion as sole treatment option 4,5,10 .

• Very high-risk SCC 5-7,9,10 .

Provider Qualifications

For purposes of Centers for Medicare and Medicaid Services (CMS), reasonable and necessary services are ordered and furnished by qualified personnel. Services will be considered medically reasonable and necessary only if performed by appropriately trained providers.

A qualified physician for this service is defined as follows: training and expertise must have been acquired within the framework of an accredited residency and/or fellowship program in the applicable specialty/subspecialty (i.e., Radiation Oncology OR by a qualified dermatology program and the dermatologist has didactic training and clinical experience in radiation treatment).

Free standing facilities (office or clinic), hospital-based practices and mobile delivery units affiliated with a Place of Service (POS) must meet federal and state local radiation protection guidelines in regard to patient safety and quality assurance as well as the physician supervision requirements. It is expected that all personnel (e.g., radiation oncologist, other qualified physician, radiation/medical physicist, radiation technologist and radiation assistant) involved in administering, supervising, and treating patients for the indications outlined in this LCD meet the regulations set forth for the state, for Medicare and the Nuclear Regulatory Commission (NRC), as applicable.

Summary of evidence (opening)

A literature search was conducted using the following key terms: SCC, BCC, SRT, EBT, RT, Mohs, surgical excision of skin cancer, IGSRT, IGEBT, recurrence rates and societal guidelines including NCCN ® , AAD, American College of Mohs Surgery (ACMS), ASTRO and ABS. Additional sources included PubMed and ECRI datasets. The literature search included published peer-reviewed literature and published societal guidelines within the last 25-30 years with greater emphasis placed upon literature from the last 15 years. Retrospective studies involving larger sample sizes were included in order to gather as much evidence as possible, although RCTs and prospective RCTs were more useful in the analysis of current evidence. Case reports and case series were excluded due to low quality of evidence. Poster presentations and unpublished reports were not included in the analysis. Published societal guidelines and recommendations were considered in the analysis as supported by the literature.

Introduction:

NMSCs or keratinocyte carcinomas are predominantly BCCs and SCCs. There are numerous treatment options available to treat these cutaneous malignancies including electrodessication and curettage, topical immunomodulators or chemotherapeutic agents, photodynamic therapy, surgical excision with and without frozen section diagnosis, MMS, RT as primary or adjuvant therapy and multi-modality therapy for advanced or systemic disease. Untreated or recurrent cutaneous malignancies can result in significant morbidity and mortality upon further progression of disease. The goal of therapy is to minimize recurrence(s) while taking into consideration associated comorbidities, size and location of the lesion(s), histology of the lesion(s) and ultimate outcome whether it be surgical or nonsurgical treatment. 4-9

Evidence-Based Guidelines for Standard of Care

The contractor cites 91 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2026-03-01
Current revision effective
2026-03-01
Last reviewed by the contractor
2025-10-22
MCD version
7

Other related documents: A60357 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L40179 cover?

Nonmelanoma skin cancers (NMSC) such as squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) are a type of keratinocyte carcinoma and are the most common malignancies reported in the United States of America(U.S.). 1-3 In 2015, Rogers et al. analyzed claims data from 2006 through 2012 for total claims filed in both the Total Claims Data Set and the Medicare Limited Data Set and found that NMSC was the most… The full 1,700-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L40179 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 4 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L40179?

The companion billing and coding article A60185 lists 51 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L40179?

A denial under LCD L40179 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A60185's 51 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.